Navigation Links
Kosan Opens Registration Program for Lead Hsp90 Inhibitor, Tanespimycin, in Multiple Myeloma
Date:8/19/2007

Tanespimycin is Industry's First Hsp90 Inhibitor to Enter Registration

Program

TIME Registration Program Utilizes New, Proprietary Tanespimycin

Formulation

HAYWARD, Calif., Aug. 2 /PRNewswire-FirstCall/ -- Kosan Biosciences Incorporated (Nasdaq: KOSN) today announced that the TIME-2 trial is open and enrolling patients. This marks the opening of Kosan's Tanespimycin in Myeloma Evaluation or "TIME" registration program for its lead Hsp90 inhibitor, tanespimycin (KOS-953). The TIME program includes two clinical trials: TIME-1 and TIME-2. TIME-1 is a pivotal Phase 3 trial to be conducted in a first-relapse patient population. TIME-2, which is designed to be supportive of the TIME-1 trial, is a Phase 2/3 trial in patients with relapsed-refractory disease. TIME-2 also has the potential to support registration in a relapsed-refractory setting. The TIME program will use Kosan's new, proprietary injectable suspension formulation of tanespimycin. Tanespimycin is the first Hsp90 inhibitor to enter a registration program.

"The opening of our TIME registration program is a major achievement for our company and a milestone in the advancement of Hsp90 inhibition, a promising new approach to cancer therapy," said Robert G. Johnson, Jr., M.D., Ph.D., Kosan's President and Chief Executive Officer. "We continue to be encouraged by the high level of durable responses we observe when tanespimycin combined with bortezomib (Velcade(R)) is administered to patients with relapsed-refractory multiple myeloma, as well as by tanespimycin's manageable safety profile. We believe that a successful outcome in the TIME-2 trial, together with data from our TIME-1
'/>"/>

SOURCE Kosan Biosciences Incorporated

Copyright©2007 PR Newswire.

Page: 1 2 3 4 5 6

Related medicine technology :

1. Kosan Presents Promising Phase 1 Data on Second-Generation Hsp90 Inhibitor, Alvespimycin, Showing Antitumor Activity in Refractory Breast and Ovarian Cancers at ASCO
2. Kosan Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Epothilone KOS-1584 at ASCO
3. Kosan Presents Data on Lead Hsp90 Inhibitor, Tanespimycin, Showing Promising Antitumor Activity in Multiple Myeloma at ASCO
4. Kosan Presents Preliminary Phase 2 Data Showing Antitumor Activity of Hsp90 Inhibitor Tanespimycin in Metastatic Melanoma at ASCO
5. Kosan Presents Preclinical Data on Nuclear Export Inhibitors, Novel Anticancer Agents, at AACR
6. Kosan Presents Preclinical Antitumor and Safety Data On Next-Generation Epothilone KOS-1803 at AACR
7. Kosan Presents Data on Cardiac Safety Profile of Hsp90 Inhibitor Tanespimycin (KOS-953) at AACR
8. Kosan Announces Data Presentations at Upcoming AACR Annual Meeting
9. Salix Pharmaceuticals Announces Positive Top Line Results of Balsalazide Tablets Registration Study
10. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
11. Pieris Progresses Proprietary Asthma Program: Validation of Pulmonary Delivery of Anticalin-Based Protein Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2015)... , May 22, 2015  Amgen (NASDAQ: ... has commenced termination of its participation in ... AstraZeneca (LON:AZN, STO:AZN and NYSE: AZN ... in development for patients with moderate-to-severe plaque ... decision was based on events of suicidal ...
(Date:5/22/2015)... BOTHELL, Wash. , May 22, 2015  BioLife Solutions, ... marketer of proprietary clinical grade hypothermic storage and ... products for cells and tissues ("BioLife" or the "Company"), ... 2015 Marcum MicroCap Conference. The Company is ... on Wednesday, May 27, 2015 at the Grand Hyatt Hotel ...
(Date:5/22/2015)... The North American dental lasers market ... to reach $90.7 million by 2019, at a CAGR of ... TOC of North America Dental Lasers Market for an analysis ... tables and figures. http://www.micromarketmonitor.com/market/north-america-dental-lasers-1771208223.html ...   Dental lasers are specifically used in ...
Breaking Medicine Technology:Amgen to terminate participation in co-development and commercialization of brodalumab 2Amgen to terminate participation in co-development and commercialization of brodalumab 3Amgen to terminate participation in co-development and commercialization of brodalumab 4Amgen to terminate participation in co-development and commercialization of brodalumab 5BioLife Solutions To Present At The 2015 Marcum MicroCap Conference In New York City 2North America Dental Lasers Market is Expected to Reach $90.7 Million by 2019, at a CAGR of 9.2% From 2014 to 2019 2North America Dental Lasers Market is Expected to Reach $90.7 Million by 2019, at a CAGR of 9.2% From 2014 to 2019 3
... Calif., May 18, 2011 Bayer HealthCare Pharmaceuticals, ... ONXX ) today announced results from a Phase ... with locally advanced or metastatic breast cancer previously ... Nexavar was associated with statistically significant improvements in ...
... of cancer patients failed to fill their initial prescriptions for oral ... the Journal of Oncology Practice ( JOP ) and ... study was based on an analysis conducted by Avalere Health LLC ... 2009. This study has also been accepted for presentation at the ...
Cached Medicine Technology:Nexavar in Combination with Chemotherapy Improves Progression-Free Survival in Patients with Advanced Breast Cancer in Phase 2 Study 2Nexavar in Combination with Chemotherapy Improves Progression-Free Survival in Patients with Advanced Breast Cancer in Phase 2 Study 3Nexavar in Combination with Chemotherapy Improves Progression-Free Survival in Patients with Advanced Breast Cancer in Phase 2 Study 4Nexavar in Combination with Chemotherapy Improves Progression-Free Survival in Patients with Advanced Breast Cancer in Phase 2 Study 5Nexavar in Combination with Chemotherapy Improves Progression-Free Survival in Patients with Advanced Breast Cancer in Phase 2 Study 6Nexavar in Combination with Chemotherapy Improves Progression-Free Survival in Patients with Advanced Breast Cancer in Phase 2 Study 7Nexavar in Combination with Chemotherapy Improves Progression-Free Survival in Patients with Advanced Breast Cancer in Phase 2 Study 8New Study Finds That 10% of Cancer Patients Abandoned Oral Anti-Cancer Drugs 2New Study Finds That 10% of Cancer Patients Abandoned Oral Anti-Cancer Drugs 3New Study Finds That 10% of Cancer Patients Abandoned Oral Anti-Cancer Drugs 4
(Date:5/25/2015)... Burke Rehabilitation Hospital will welcome Samuel White, ... City, to speak at Burke on Wednesday, June 3. The ... Lecture series, will take place at 4:30 p.m. on Burke’s ... of Stanford White of McKim, Mead and White, the famed ... years ago. , “We are thrilled to welcome Samuel White ...
(Date:5/24/2015)... Metamora, Michigan (PRWEB) May 24, 2015 ... for concerns about hair loss. Although it is unclear ... that there are environmental factors such as metabolism, nutritional ... contribute. Since they offer a comprehensive approach to evaluating ... and post-menopausal woman, they can help patients find a ...
(Date:5/24/2015)... (PRWEB) May 24, 2015 EnviroLeather™ ... launches “InkGard™ Plus” – a classic, rugged leather ... polymer allowing difficult stains, including ink, to be ... different colors suitable for corporate, healthcare, hospitality and ... line with EnviroLeather’s goal of developing products that ...
(Date:5/24/2015)... Medicx Media Solutions http://www.medicxmedia.com ... Jay Krihak as its head of programmatic strategy ... its expertise and leadership position in the data ... sectors. , Krihak is an experienced, award-winning agency ... led sales planning teams for mobile platform Jumptap. ...
(Date:5/23/2015)... On May 13, Nithyananda Yoga Foundation ... yogic power learned through meditation and initiation at Special ... India. , Yogamaatha, a nine-year-old girl from North Carolina, ... professionals attending the 2015 Business Advocacy Summit at Capitol ... , In a demonstration that lasted three hours, ...
Breaking Medicine News(10 mins):Health News:Burke Rehabilitation Hospital Welcomes Architect Samuel White, Descendant of McKim, Mead and White, for Legacy Lobby Lecture 2Health News:Burke Rehabilitation Hospital Welcomes Architect Samuel White, Descendant of McKim, Mead and White, for Legacy Lobby Lecture 3Health News:Women's Excellence Now Treats Menopausal Hair Loss 2Health News:EnviroLeather By LDI Launches "InkGard Plus" - Stain Resistant Faux Leather 2Health News:Medicx Media Solutions Expands Executive Team 2Health News:Nine-Year-Old Reads Blindfolded at Business Advocacy Summit 2Health News:Nine-Year-Old Reads Blindfolded at Business Advocacy Summit 3
... the NHS proposal to allow nurses to perform routine, ... as being equivalent to entrusting airhostesses // with the ... Medical Association (BMA) has been urged to alert the ... operations on patients. More than 130 doctors have indeed ...
... by the American Medical Association has left its readers tipsy with ... ,A survey of 644 female college students has revealed that breaking ... having fun in life. Three out of four women seem to ... drinking meant bingeing on booze, getting them all sick and drunk. ...
... is under pressure as it is asked to improve its ... who has had deep// ties with the company has her ... of directors for six years. Hillary Clinton said that her ... ,But in recent months, as the company has ...
... the Norfolk and Norwich University Hospital have been given the ... to women who test positive for her-2 gene. ... the therapeutic advisory groups, and the primary care trusts have ... the N&N. "About one in five women with breast cancer ...
... that British Asians are at least 50 percent more likely ... European origin. One in five has also developed type 2 ... in the UK. ,Of immediate concern are the ... blood pressure amongst South East Asians in the UK, said ...
... huge study involving 38 populations across 21 countries, reserachers have ... dropping.// ,"Blood pressure did not go down in ... of them," said Prof Tunstall-Pedoe, who led the World Health ... change was not great, but it did appear to have ...
Cached Medicine News:Health News:Doctors Protest Against Allowing Nurses To Perform Minor Surgeries 2
Universal vacuum pump (capacity 34 L/min, 8 mbar vacuum abs.)...
... Combines BchiVac V-500 with Vacuum Controller V-800 ... switching mechanism turns V-500 on and off as needed ... Model V-500 is a powerful PTFE membrane ... Applications Ideally suited for use with up ...
... to the powerful PTFE membrane vacuum pump line ... an ultimate vacuum of 1 mbar or a ... For use with vacuum drying ovens and ... lab size up to industrial size rotary evaporators ...
... Model V-500 is a powerful PTFE membrane vacuum ... Applications Ideally suited for use with ... vacuum source for instruments including vacuum ovens, concentrators, ... Product features PEEK head resistant to chemicals ...
Medicine Products: